The Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 6.5% CAGR during the forecast period (2021-2027).
In the male reproductive system, the prostate is a walnut-sized gland that surrounds the urethra. This gland's major job is to emit a fluid that combines with the fluids from other glands and sperm cells from the testicles to form semen. BPH (benign prostatic hyperplasia) is a non-cancerous enlargement of the prostate gland. This causes increased frequency of urination at night which is majorly called nocturia, urinary hesitancy, and urinary retention because the urine flow from the bladder is blocked.
Because of symptoms like urine leakage, BPH has a substantial impact on the patient's quality of life. It can lead to more significant health problems, such as bladder damage, bladder stones, kidney damage, and urinary tract infections, if left untreated for a long time (UTIs).
However, the incidence of BPH in mainland China did not show a consistent trend, and a prevalence map centered on a geographic information system (GIS) revealed an unequal regional distribution. Further, due to the increased population of the country, more people are likely to attain BHP. This factor would further accelerate the demand for the benign prostatic hyperplasia therapeutics in the region.
The China market dominated the Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $786.3 million by 2027. The Japan market is poised to grow a CAGR of 5.9% during (2021 - 2027). Additionally, The India market would showcase a CAGR of 7.5% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Benign Prostatic Hyperplasia Therapeutics Market is Projected to reach USD 7.4 Billion by 2027, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 Asia Pacific Mono Drug Therapy Market by Country
3.2 Asia Pacific Combination Drug Therapy Market by Country
Chapter 4. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 Asia Pacific Alpha Blockers Market by Country
4.2 Asia Pacific 5- alpha Reductase Inhibitors Market by Country
4.3 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 China Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 Japan Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 India Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 South Korea Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.5 Singapore Benign Prostatic Hyperplasia Therapeutics Market
5.5.1 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.5.2 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.6 Malaysia Benign Prostatic Hyperplasia Therapeutics Market
5.6.1 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.6.2 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.7 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market
5.7.1 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.7.2 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 4 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 5 Asia Pacific Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 6 Asia Pacific Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 7 Asia Pacific Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 8 Asia Pacific Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 9 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 10 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 11 Asia Pacific Alpha Blockers Market by Country, 2017 - 2020, USD Million
TABLE 12 Asia Pacific Alpha Blockers Market by Country, 2021 - 2027, USD Million
TABLE 13 Asia Pacific 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 14 Asia Pacific 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 15 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 16 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 17 Asia Pacific Others Market by Country, 2017 - 2020, USD Million
TABLE 18 Asia Pacific Others Market by Country, 2021 - 2027, USD Million
TABLE 19 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
TABLE 20 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
TABLE 21 China Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 22 China Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 23 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 24 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 25 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 26 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 27 Japan Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 28 Japan Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 29 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 30 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 31 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 32 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 33 India Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 34 India Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 35 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 36 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 37 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 38 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 39 South Korea Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 40 South Korea Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 41 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 42 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 43 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 44 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 45 Singapore Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 46 Singapore Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 47 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 48 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 49 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 50 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 51 Malaysia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 52 Malaysia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 53 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 54 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 55 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 56 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 57 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 58 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 59 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 60 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 61 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 62 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 63 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 64 key information – Astellas Pharma, Inc.
TABLE 65 Key Information – Eli Lilly and Company
TABLE 66 Key Information – Allergan PLC
TABLE 67 key Information – Merck Group
TABLE 68 Key Information – Boehringer Ingelheim International GmbH
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Sanofi S.A.
TABLE 71 Key Information – Pfizer, Inc.
TABLE 72 Key Information – Abbott Laboratories
List of Figures
FIG 1 Methodology for the research